Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma

Jeffrey Matous • 6 Dec 2014
ASH 2014
Multiple Myeloma Carfilzomib Dexamethasone Lenalidomide

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffrey Matous (Colorado Blood Cancer Institute, Denver, CO) discusses the randomised, open-label, multicentre phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma.

More from Jeffrey Matous

4:27
ASH 2020: myeloma transplantation highlights
Jeffrey Matous • 11 Dec 2020
3:47
ALLO-715 and ALLO-647: novel CAR-T products in R/R myeloma
Jeffrey Matous • 11 Dec 2020

Related Videos

1:33
The importance of QoL in guiding myeloma therapy
Karthik Ramasamy • 24 Mar 2019
2:40
CAR T-cell therapy to revolutionize multiple myeloma?
Mohamad Mohty • 19 Feb 2019
1:26
Sagar Lonial discusses his top myeloma research picks
Sagar Lonial • 1 Apr 2019
2:30
Cellular therapy and SCT in synergy
Mohamad Mohty • 25 Mar 2019
The content of VJHemOnc is intended for healthcare professionals